Should You Buy or Sell Abbott Laboratories Stock Ahead of Its Upcoming Earnings?

Abbott Laboratories (ABT) is scheduled to release its second-quarter earnings on July 17, 2025, with consensus estimates projecting $1.25 EPS on $11.02 billion in sales, an increase from the prior year. Historically, ABT stock has shown a tendency for negative one-day returns following earnings announcements in 60% of instances over the past five years, with a median decline of 2.4%, though positive returns occurred 40% of the time with a median gain of 3.0%. These historical patterns and the correlation between short-term and medium-term post-earnings returns are key considerations for event-driven traders assessing pre- or post-earnings positioning strategies.

Analysis

Abbott Laboratories is approaching its Q2 2025 earnings release on July 17 with a notable divergence between fundamental expectations and historical stock performance. Analyst consensus projects robust year-over-year growth, with earnings expected to reach $1.25 per share on $11.02 billion in sales, up from $1.14 and $10.38 billion respectively in the prior-year quarter. This positive outlook is supported by strong trailing-twelve-month fundamentals, including $42 billion in revenue and $7.1 billion in operating profit. However, historical trading data presents a cautionary signal for event-driven investors. Over the last five years, ABT's stock has registered a negative one-day return following 60% of its earnings announcements, with a median decline of -2.4%. While the median gain on positive days was a slightly larger 3.0%, the negative skew is significant. A more recent three-year trend shows an improvement in this pattern, with the probability of a positive one-day return rising to 50%, suggesting a potential shift in market reaction that will be tested by the upcoming report.

Key Decisions for Investors

• Given the 60% historical probability of a negative post-earnings reaction over the last five years, short-term traders should exercise caution and may consider positioning for volatility or waiting for the initial market reaction to subside before entering a trade.
• Long-term investors focused on fundamentals might view any potential price weakness following the earnings release as a buying opportunity, provided the company meets or exceeds its strong growth forecasts and offers positive forward guidance.
• The key determinant for the stock's direction will be the magnitude of the earnings beat or miss relative to the $1.25 EPS estimate and, critically, the outlook provided by management, which could either validate the historical negative bias or confirm the more recent, neutral 50/50 trend.